This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

RAPT Therapeutics 향후 성장

Future 기준 점검 0/6

RAPT Therapeutics 의 수익은 연간 29% 감소할 것으로 예상되는 반면, 연간 수익은 84.4% 로 증가할 것으로 예상됩니다. EPS는 연간 15.4% 만큼 쇠퇴할 것으로 예상됩니다.

핵심 정보

-29.0%

이익 성장률

-15.44%

EPS 성장률

Biotechs 이익 성장	25.3%
매출 성장률	84.4%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	03 Mar 2026

최근 향후 성장 업데이트

Recent updates

Seeking Alpha • Jan 20

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Summary RAPT Therapeutics, Inc. is being acquired by GSK plc, aka GlaxoSmithKline, for $2.2 billion, driven by its promising anti-IgE antibody ozureprubart. Ozureprubart offers a potential best-in-class profile with extended half-life, enabling dosing every 8–12 weeks versus XOLAIR’s 2–4 weeks. The Phase 2b prestIgE trial is underway for IgE-mediated food allergy, leveraging strong proof-of-concept data in chronic spontaneous urticaria. I maintain a Buy rating on RAPT, citing pipeline progress, the acquisition that happened, and the broad applicability of ozureprubart to IgE-mediated disorders. Read the full article on Seeking Alpha

분석 기사 • Jul 16

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Summary RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity. If ph1b results are replicated, I expect the ph2 readout to be positive with available patients, despite premature halting of the trial. Subsequently, I expect the lifting of the FDA clinical hold. Read the full article on Seeking Alpha

분석 기사 • Feb 21

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Sep 12

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • May 10

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Feb 07

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

분석 기사 • Oct 12

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Oct 15

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

분석 기사 • Jun 08

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

분석 기사 • Mar 15

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

이익 및 매출 성장 예측

NasdaqGM:RAPT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	N/A	-220	-183	N/A	4
12/31/2027	N/A	-162	-142	N/A	4
12/31/2026	N/A	-91	-99	N/A	4
12/31/2025	N/A	-83	-79	N/A	4
9/30/2025	N/A	-106	-87	-87	N/A
6/30/2025	N/A	-106	-92	-92	N/A
3/31/2025	N/A	-117	-109	-109	N/A
12/31/2024	N/A	-130	-83	-83	N/A
9/30/2024	N/A	-107	-101	-101	N/A
6/30/2024	N/A	-120	-105	-105	N/A
3/31/2024	N/A	-118	-106	-106	N/A
12/31/2023	N/A	-117	-98	-97	N/A
9/30/2023	N/A	-109	-93	-92	N/A
6/30/2023	N/A	-99	-89	-87	N/A
3/31/2023	1	-93	-75	-74	N/A
12/31/2022	2	-84	-72	-71	N/A
9/30/2022	2	-79	-70	-69	N/A
6/30/2022	3	-76	-65	-64	N/A
3/31/2022	3	-73	-63	-63	N/A
12/31/2021	4	-69	-62	-61	N/A
9/30/2021	4	-64	-56	-56	N/A
6/30/2021	5	-60	-54	-53	N/A
3/31/2021	5	-56	-46	-46	N/A
12/31/2020	5	-53	-41	-40	N/A
9/30/2020	4	-53	-31	-31	N/A
6/30/2020	2	-49	-33	-33	N/A
3/31/2020	1	-47	-36	-36	N/A
12/31/2019	N/A	-43	-36	-35	N/A
9/30/2019	N/A	-39	-42	-39	N/A
6/30/2019	N/A	-40	N/A	-36	N/A
3/31/2019	N/A	-37	N/A	-34	N/A
12/31/2018	N/A	-36	N/A	-33	N/A

애널리스트 향후 성장 전망

수입 대 저축률: RAPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: RAPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: RAPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: RAPT 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 매출: RAPT 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: RAPT의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/03/05 15:35
종가	2026/03/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

RAPT Therapeutics, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Gao Yi Chen	Berenberg
Guyn Kim	BMO Capital Markets Equity Research
Zegbeh Jallah	Capital One Securities, Inc.

This company has been acquired

RAPT Therapeutics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased by 18% to US$18.14

Price target decreased by 21% to US$33.63

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$50.29

Recent updates

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

RAPT Therapeutics, Inc. Announces William Ho Leaves as Chief Medical Officer on December 31, 2025

RAPT Therapeutics, Inc. Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

RAPT Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.00002 million.

RAPT Therapeutics, Inc. and Shanghai Jeyou Pharmaceutical Co., Ltd. Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate

RAPT Therapeutics, Inc. Announces Board and Committee Appointments

RAPT Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Minimum Closing Bid Price Rule

RAPT Therapeutics, Inc., Annual General Meeting, May 29, 2025

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Wendye R. Robbins Does Not Stand for Election as Director of Rapt Therapeutics, Inc

Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904

RAPT Therapeutics, Inc. Announces Board Changes

RAPT Therapeutics, Inc. announced that it expects to receive $149.976555 million in funding from a group of investors

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Rapt Therapeutics Approves Reduction to Their Workforce

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Price target decreased by 18% to US$18.14

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

RAPT Therapeutics, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Price target decreased by 21% to US$33.63

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon (RPT193) in Atopic Dermatitis and its Phase 2a Trial in Asthma

New major risk - Revenue and earnings growth

RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations

RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

New major risk - Revenue and earnings growth

New minor risk - Share price stability

RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

New major risk - Revenue and earnings growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.69 loss in 1Q 2022)

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

Insider recently bought US$98k worth of stock

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Insufficient new directors

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$50.29

Price target decreased to US$53.00

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$77k worth of stock

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$69k worth of stock

Chief Scientific Officer exercised options and sold US$65k worth of stock

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.60 loss in 3Q 2020)